Skip to main navigation

Manage Cookie Consent

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

Privacy and Cookie Notice {title} {title}

Home
About
Pipeline
Investors
Contact

News & Events

Company Overview
News & Events
- News Releases
- Events & Presentations
Stock Information
Financial Information
Corporate Governance
IR Resources
- Email Alerts
- Contact IR

News Category

Year

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 20, 2024

PDF Version

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 19, 2024

PDF Version

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Nov 07, 2024

PDF Version

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Nov 05, 2024

PDF Version

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 31, 2024

PDF Version

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Oct 22, 2024

PDF Version

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Sep 09, 2024

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 08, 2024

PDF Version

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 06, 2024

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Past Events

Fourth Quarter 2023 Financial Results and Corporate Update Conference Call

Mar 14, 2024 at 8:30 AM EDT

Listen to webcast

Presentations

Corporate Overview 1 MB

Subscribe

Sign up for alerts to stay up to date on Quoin Pharmaceuticals.

News:

Dec 20, 2024

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 19, 2024

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

2024 © Quoin Pharmaceuticals, Inc. Privacy Policy